These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 34288482)
21. [What is new in basal cell carcinoma?]. Heppt M; von Braunmühl T; Berking C Hautarzt; 2016 Nov; 67(11):876-883. PubMed ID: 27654826 [TBL] [Abstract][Full Text] [Related]
22. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma. Leavitt E; Lask G; Martin S Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379 [TBL] [Abstract][Full Text] [Related]
23. [Vismodegib in metastasized basal cell carcinoma]. Reinders MG; Dirix L; Mosterd K; van Doorn R Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044 [TBL] [Abstract][Full Text] [Related]
24. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation. Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221 [TBL] [Abstract][Full Text] [Related]
26. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905 [TBL] [Abstract][Full Text] [Related]
27. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567 [TBL] [Abstract][Full Text] [Related]
28. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394 [TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507 [TBL] [Abstract][Full Text] [Related]
30. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Meani RE; Lim SW; Chang AL; Kelly JW Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162 [TBL] [Abstract][Full Text] [Related]
32. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma. Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621 [TBL] [Abstract][Full Text] [Related]
33. Systemic Targeted Treatments for Basal Cell Carcinoma. Svoboda SA; Johnson NM; Phillips MA Cutis; 2022 Jun; 109(6):E25-E31. PubMed ID: 35960978 [TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207 [TBL] [Abstract][Full Text] [Related]
35. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787 [TBL] [Abstract][Full Text] [Related]
36. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338 [TBL] [Abstract][Full Text] [Related]
37. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature. Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689 [TBL] [Abstract][Full Text] [Related]
38. Management of high-risk and advanced basal cell carcinoma. Puig S; Berrocal A Clin Transl Oncol; 2015 Jul; 17(7):497-503. PubMed ID: 25643667 [TBL] [Abstract][Full Text] [Related]
39. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report. Awad R; Andrade JCB; Mousa H; Mahmoud F Perm J; 2018; 22():17-181. PubMed ID: 30005721 [TBL] [Abstract][Full Text] [Related]